Potential Biomarkers for Prediction of the Efficacy and Safety of CAR T Cell Treatment in Systemic Lupus Erythematosus

WANG Yiyang,LÜ Liangjing

DOI: https://doi.org/10.16150/j.1671-2870.2024.03.003

2024-01-01

Abstract:Systemic lupus erythematosus(SLE)is a complex autoimmune disease for which traditional treatments of-ten show limited efficacy in severe and refractory cases.Recently,chimeric antigen receptor(CAR)T cell therapy has emerged as a novel immunotherapy strategy,demonstrating significant efficacy in preliminary studies for SLE treatment.Biomarkers are crucial for the precise assessment of treatment efficacy and safety.Biomarkers for monitoring the efficacy of CAR T cell therapy include traditional markers and markers related to CAR T therapy.Traditional markers for SLE disease monitoring,such as decreased titers of serum anti-double-stranded DNA,anti-single-stranded DNA,anti-nucleosome auto-antibodies,normalization of serum complement levels,and improvement of urine protein/creatinine ratio,indicate that the disease is effectively controlled and can still be used for baseline follow-up and disease monitoring during CAR T cell therapy.B cell markers indicating effective CAR T therapy include a decrease in the number of B cells after infusion,a B cell phenotype dominated by the naive B cell,and a significant decrease in the proportion of memory B cells and plasma-blasts.Regarding T cell markers related to CAR T therapy,the high proportion of naive T cell(CD45RA+CD27+)and cen-tral memory T cell(CD45RA-CD62L+CD27+)subsets before infusion indicate stronger anti-tumor efficacy;The initial ex-pression of transcription factors associated with early memory differentiation on patients'CAR T cells,such as T cell factor 7(TCF7)and lymphoid enhancer-binding factor 1(LEF1),suggest that these patients may be sensitive to CAR T therapy.After infusion,high expression of T cell activation markers(CD25,CD69 and CD137),and exhaustion markers(CD57,PD-1,and Tim-3)indicate that T cells are in a state of dysfunction,with limited expansion,cytokine secretion and cell killing capabilities.Safety markers,including effector cytokines secreted by CAR T cells[interleukin(IL)-2 and IFN-γ]and cyto-kines produced by monocytes and macrophages(IL-1 and IL-8),can be used to monitor the most common toxicities and side-effects of CAR T-cell therapies,cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syn-drome(ICANS).High levels of serum macrophage inflammatory protein-1α(MIP-1α)are of high value for predicting the risk of severe CRS and ICANS after CAR T-cell therapy.In addition,haematotoxicity markers include baseline platelet count and absolute neutrophil count,and an infection-related prediction model consisting of IL-8,IFN-γ and IL-1β are effective in predicting the risk of severe infection in patients after infusion.The design of the CAR receptor structure,the chemothera-peutic modality used to remove the lymphocytes,as well as the choice of treatments that the patient had received and the au-toimmune status,all affect the efficacy and safety.A comprehensive and standardised testing and evaluation system should be included in current and future clinical studies to provide a comparative standard for the use of CAR T-cell therapy in au-toimmune diseases such as SLE.